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Abstract
Background: The complement system is suggested to be involved in the pathogenesis of osteoarthritis (OA), and
proinflammatory cytokines may play a role in OA development by inducing proteases. The association between
complement factors, cytokines and OA has not been investigated. The aim of the present study was to explore the
involvement of the complement system after knee trauma and in OA.
Methods: C4d, C3bBbP and soluble terminal complement complex (sTCC) resulting from complement activation
were immunoassayed in synovial fluid from subjects with healthy knees (reference), OA, rheumatoid arthritis (RA;
positive control), pyrophosphate arthritis (PPA; positive control) and knee injury; other biomarkers were previously
assessed. Magnetic resonance imaging was used to assess joint injuries.
Results: Compared with levels in the reference group, the median concentrations of C4d, C3bBbP and sTCC in the
OA, RA, PPA and knee injury groups were 2- to 34-fold increased (p < 0.001 to p = 0.044). For the knee injury group,
the median concentrations of C4d, C3bBbP and sTCC were 5- to 12-fold increased (p < 0.001) at the day of injury;
after 3–12 weeks, C3bBbP and sTCC concentrations were similar to reference levels; and C4d was still increased several
years after injury. In the 0–12 weeks period after injury, the concentrations of C4d, C3bBbP and sTCC correlated
positively with levels of interleukin (IL)-1β, IL-6 and tumour necrosis factor α (rs range 0.232–0.547); none of the
measured complement factors correlated with proteolytic fragments of aggrecan or cartilage oligomeric matrix
protein. Knees with osteochondral fracture, with or without disrupted cortical bone, had higher concentrations of
C4d (p = 0.014, p = 0.004) and sTCC (p = 0.004, p < 0.001) compared with knees without fractures.
Conclusions: The complement system is activated in OA and after knee injury. Following knee injury, this
activation is instant and associated with inflammation as well as with the presence of osteochondral fractures.
Keywords: Complement, Knee injury, Osteoarthritis, Synovial fluid
Background
The complement system as a part of innate immunity
is one of the first lines of defence against invading
pathogens. Apart from this basic, evolutionarily con-
served function, it also plays a role in scavenging of cel-
lular debris and immune complexes, opsonisation and
guidance of adaptive immunity by anaphylatoxins and
stimulation of B and T lymphocytes [1]. Importantly,
complement is an aggressive system capable of target-
ing even its own cells and tissues when improperly reg-
ulated by endogenous inhibitors and/or autoantibodies,
or because of gain-of-function mutations in comple-
ment components [1, 2]. Such autoreactivity was shown
to be an important constituent of pathological mecha-
nisms of inflammatory and autoimmune diseases,
including rheumatoid arthritis (RA) [3]. Cartilage deg-
radation products released in the course of joint degen-
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Joint injury is a major risk factor for the development of
post-traumatic osteoarthritis (OA) [8]. Mechanical injury
to the joint leads to haemarthrosis, death of chondrocytes
and bone cells [9, 10], as well as damage to the tissue
extracellular matrix (ECM) directly or mediated by chon-
drocytes and synoviocytes via increased expression and ac-
tivation of matrix-degrading enzymes stimulated by
proinflammatory cytokines [11]. Furthermore, comple-
ment activation has been implicated in the connective tis-
sue repair and inflammatory response initiated by trauma
[12, 13]. These observations led us to hypothesize that
mechanical joint injury may be an initial trigger of local
inflammation, including activation of complement, and
that subsequent ECM erosion of injured joints may
reinforce complement activation in a positive feedback
manner. Monitoring of the complement activation profile
after injury could give information potentially important
for the design of therapeutic strategies.
We therefore investigated complement activation in
OA and the time-dependent activation after knee injur-
ies. RA and pyrophosphate arthritis (PPA) samples were
used as positive controls for complement activation. We
measured complement activation products characteristic
of classical and/or lectin (C4d) and alternative (C3bBP)
pathways, as well as the soluble terminal complement
complex (sTCC), in the synovial fluid from different pa-
tient diagnostic groups (Fig. 1).
Methods
Subjects
In our cross-sectional convenience cohort, 294 patients
with knee injury had synovial fluid aspirated once from
their knees without lavage; of those, 112 subjects did not
fulfil the inclusion criteria of a randomized controlled trial
[14], and the remaining 182 subjects had been studied in
previous cross-sectional investigations [15–18] (Table 1).
Fig. 1 A scheme of the complement system. Complement can be activated via three different routes. The classical and lectin pathways have
their own specific pattern recognition molecules (PRMs), whereas the alternative pathway is activated by a spontaneous tick-over of C3 and
deposition of C3b molecules onto permissive surfaces, which is facilitated by properdin (P). All pathways converge at the stage of C3 convertases,
which catalyse breakdown of C3 into C3a and C3b molecules. When C3b molecules bind to the convertase complex, it gives rise to the C5
convertase. Except for the triggers indicated for each pathway in the scheme, apoptotic and necrotic cellular debris as well as degradative protein
fragments from the extracellular matrix can also trigger all three pathways [4, 32]. In red and boldface type are the markers of complement activation
analysed in our study: C4d, the end degradation product of C4b; C3bBbP, a soluble form of alternative C3 convertase including properdin; and sTCC,
soluble terminal complement complex (a soluble form of C5b-9). Factor D Serine protease that cleaves factor B, Igs Immunoglobulins, MASP Mannose-
binding lectin-associated serine protease, MBL Mannose-binding lectin
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On the basis of time between injury and synovial fluid as-
piration, the subjects with knee injury were stratified into
a recent injury group (sampling 0–83 days, or 0–12 weeks,
after injury) and an old injury group (sampling 1–37 years
after injury), and these groups were substratified by time
after injury into groups of 24–46 subjects each (Table 1).
From another convenience cohort, we used 23 reference
subjects (without a history of knee symptoms or knee in-
jury, or with normal findings in clinical, radiographic and
arthroscopic examinations), and 24 patients with OA, 32
with RA and 25 with PPA (RA and PPA, positive controls
for complement activation) who had synovial fluid aspi-
rated from their knees (Table 1). These samples have been
used in previous investigations [14–19]. For the patients
in the OA and old injury groups, an OA score (ranging
from 1 to 10) for their affected joints was assessed by
arthroscopy and radiography, with a score of 1 repre-
senting a normal joint by arthroscopy and radiography,
scores of 2–5 representing an increasing extent and se-
verity of fibrillation and clefts by arthroscopy and
appearing normal on a radiograph, and scores of 6–10
representing increasing degrees of radiographic joint
space narrowing [20].
Synovial fluid was aspirated (without lavage) from each
subject at one time point only, centrifuged at 3000 × g
for 10 minutes at 4 °C, and the supernatants were then
stored at −80 °C.
Analysis of C4d, C3bBbP and sTCC in synovial fluid
Concentrations of C4d [21], C3bBbP and sTCC (C5b-
9) [22] in synovial fluid were measured by performing
sandwich enzyme-linked immunosorbent assays (ELISAs).
Briefly, for the C4d assay, a capture antibody against a
C4d neoepitope, together with a mouse anti-C4d detec-
tion antibody (A253; Quidel, San Diego, CA, USA),
followed by peroxidase-conjugated goat anti-mouse
(P0447; Dako, Carpinteria, CA, USA) were used. For
the C3bBbP assay, a capture antibody against properdin
(A235; Quidel), together with a rabbit anti-C3c detec-
tion antibody (P0062; Dako), followed by peroxidase-
conjugated goat anti-rabbit (P0448; Dako) were used.
For the sTCC assay, we used a monoclonal capture
antibody against a C9 neoepitope (clone ae11,
HM2167; Hycult Biotech, Uden, the Netherlands), to-
gether with an in-house biotinylated monoclonal anti-
C6 antibody (A219; Quidel), followed by a streptavidin-
Table 1 Characteristics of the study subjects
Main diagnostic groups Subgroups of injury Duration, range (median) n (% women) Age in years, median (range) Differences in age,
p value
Reference subjects – NA 23 (22) 26 (15–58) –
Osteoarthritisa – 0–14.8 years (2.7) 24 (42) 64 (36–86) <0.001
Rheumatoid arthritisb – 0–43.0 years (10) 32 (63) 64 (32–83) <0.001
Pyrophosphate arthritis – 0–9.8 years (0.01) 25 (40) 75 (41–92) <0.001
Knee injuryc – 0–36.9 years (0.02) 294 (27) 29 (13–65) 0.842
Recent injury 0–83 days (4) 219 (25) 26 (13–64) 0.705
Recent injury, substratification 0 days (0) 35 (23) 30 (14–47) 0.991
1 day (1) 39 (21) 24 (13–57) 0.211
2–3 days (3) 31 (29) 26 (16–54) 0.914
4–7 days (5) 46 (28) 25 (14–64) 0.492
8–22 days (11) 44 (30) 23 (14–57) 0.151
23–83 days (32) 24 (13) 38 (21–59) 0.033
Old injuryd 1–36.9 years (3.3) 75 (33) 32 (18–65) 0.090
Old injury, substratification 1–3 years (2.0) 35 (40) 33 (18–61) 0.149
3.01–36.9 years (5.1) 40 (28) 30 (18–65) 0.121
The injury groups are presented with stratification based on time between injury and synovial fluid aspiration. Differences in age between patients and reference
groups were analysed using Student’s t test, and significant values (p < 0.05) are indicated by boldface type. Duration refers to time between injury or onset of
disease and sampling. NA Not applicable
aSymptomatic and/or radiographically diagnosed idiopathic osteoarthritis (with no history of knee trauma), with information of disease duration from 17 of 24
patients. The OA score for the OA group was as follows: median = 7, range = 3–9 (information from 15 of 24 patients)
bRheumatoid arthritis, with information of disease duration from 29 of 32 patients, taking the following medications: no information (n = 1), no medication (n = 3),
non-steroidal anti-inflammatory and/or disease-modifying drugs (n = 28)
cThe clinical diagnosis of the subjects with knee injury was as follows: isolated anterior cruciate ligament (ACL) or posterior cruciate ligament (PCL) injuries (ACL
n = 39, PCL n = 4), ACL injury with meniscal tear (n = 69), ACL injury with meniscal tear and other ligament injuries (n = 37), ACL injury with other ligament injuries
(n = 47), isolated meniscal tear (n = 58), meniscal tear with other (not ACL) ligament injuries (n = 7), patellar dislocation with or without soft tissue injuries (n = 13),
other types of injuries (medial or lateral collateral ligament tears n = 7, give-way n = 2), no signs of soft tissue injury (n = 10)
dSix patients in the old injury group had post-traumatic OA (based on OA score ≥5 [20]), and the group had the following OA score: median = 2, range = 1–8
(information from 63 of 75 patients)
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HRP reagent. The read-out of each of these assays was
given in complement activation units (CAU), a defined
arbitrary unit set for the International Complement
Standard #2 sample, which is serum pooled from ap-
proximately 1000 healthy individuals and incubated
with activators of all three complement pathways [22].
Other biomarkers and cytokines
A subset of synovial fluid samples from the recent
injury group (n = 111–181) were previously assayed
for the following biomarkers: sulfated glycosamino-
glycan (sGAG, a marker for total aggrecan); ARGS
neoepitope of aggrecan (ARGS-aggrecan from aggre-
canase cleavage at the TEGE392↓393ARGS site of
aggrecan); osteocalcin, secreted protein acidic and
rich in cysteine (SPARC), also known as osteonectin,
osteopontin, cartilage oligomeric matrix protein
(COMP); type II collagen epitope (C2C); osteopontin;
and the proinflammatory cytokines interleukin (IL)-
1β, IL-6, IL-8 and tumour necrosis factor α (TNF-α)
[14, 17, 19, 23].
Image acquisition and analysis
Magnetic resonance imaging (MRI) using a 1.5-Tesla
scanner was conducted in a subfraction of the recent in-
jury group as described elsewhere [19]. Briefly, synovial
fluid was aspirated 0–23 days after injury, and MRI
scans were acquired within a median of 8 days (range 1–
38) after injury in 98 of the 219 subjects of the recent in-
jury group. MRI studies were assessed by an experienced
musculoskeletal radiologist for anterior cruciate ligament
(ACL) tears, meniscal tears, post-traumatic bone marrow
lesions (BMLs), apparent cartilage defects (evident ir-
regularity of cartilage) and osteochondral (OC) fractures
with or without disrupted cortical bone. Such fractures
were considered a proxy for the strength of impact
forces applied over the articular surface at the time of
injury [19, 24]. These factors were classified as present
or absent for the entire knee.
Statistics and calculations
According to Shapiro-Wilk tests, synovial fluid C4d,
C3bBbP and sTCC concentrations were not normally
distributed in all diagnostic groups; therefore, when all
groups were compared, non-parametric analysis was
conducted. Between-groups comparisons were made
using Mann-Whitney rank-sum tests, and for correl-
ation analysis, Spearman’s rank correlation (rs) ana-
lysis was used. Student’s t test was used for
comparison of age between subject groups. All of
these tests were two-tailed. For a subset (n = 98) of the
recent injury group, one-way analysis of covariance
(ANCOVA) was used to investigate differences in syn-
ovial fluid C4d, C3bBbP and sTCC concentrations
with regard to structural joint damage as visualized by
MRI. After log10 transformation, the data were nor-
mally distributed according to the Shapiro-Wilks test,
and ANCOVA was done with adjustments for days be-
tween injury and synovial fluid aspiration, age and sex.
The mean and 95 % CI were calculated using log10-
transformed data, but they are presented as linear
data.
Samples with concentrations below the lower limit
of detection (LLOD) were imputed and given a value
equal to half the value of the LLOD. The synovial fluid
concentrations of C4d, C3bBbP and sTCC, as well as
the amount of samples with imputed values (between
0 and 17 % depending on groups) in the different sub-
ject groups, are provided in Additional file: Table S1.
In the group-level analysis, the imputed values were
included. In the correlation analysis, samples with and
without (measured values only) imputed values were
analysed, but significance was considered only when
both analyses showed correlation, and the presented
data (rs and p values) include imputed values. IBM
SPSS version 21 software (IBM, Armonk, NY, USA)
was used for statistical analysis, and p values less than
0.05 were considered significant. Expressions such as
“higher” and “increase” in the text are based on statis-
tically significant differences.
Results
Technical performance of the C4d, C3bBbP and sTCC
ELISAs with synovial fluid
The LLOD and upper limit of detection (ULOD) for
the C4d ELISA were 0.05 and 25 CAU, respectively
(Additional file 2: Table S2). Within this range, good di-
lution linearity was observed for synovial fluid control
samples diluted 1:5 to 1:40, mean recoveries between
97 % and 104 %, and reference and patient synovial
fluid samples were used at the same dilutions. The
LLOD and ULOD for the C3bBbP and sTCC assays
were 0.05 and 50, respectively, and 0.02 and 10 CAU,
respectively (Additional file 2: Table S2). The control
synovial fluid samples showed poor dilution linearity in
the C3bBbP and sTCC assays, mean recoveries were
54–150 % for C3bBbP and 60–141 % for sTCC; there-
fore, all analysis of the reference and patient synovial
fluid samples were done at the same dilution of 1:20.
Spiking the synovial fluid control samples with different
amounts of standards showed good recovery for the
C4d and C3bBbP assays (mean recoveries between
79 % and 99 % and between 96 % and 107 %, respect-
ively), while the sTCC assay showed lower recovery of
68–77 %. As also shown for measurements in serum
and plasma samples [21, 22], the C4d, C3bBbP and
sTCC concentrations in synovial fluid were not affected
by repeated freeze-thaw cycles, tested for up to
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15 cycles (Additional file 2: Table S2). The intra-assay
coefficient of variation (CV, within plates) for the syn-
ovial fluid control samples was approximately similar
between the C4d, C3bBbP and sTCC assays (between
9 % and 10 %), while the inter-assay CV (between
plates) was higher for the C3bBbP and sTCC assays
(both 23 %) compared with the C4d assay (16 %)
(Additional file 2: Table S2).
Concentrations of C4d, C3bBbP and sTCC in synovial fluid
were higher in the arthritis groups than in the reference
group
The concentrations of C4d, C3bBbP and sTCC were
higher in the OA, RA and PPA groups than in the refer-
ence group. Median levels increased between 4- and 34-
fold (C4d), 2- and 5-fold (C3bBbP), and 4- and 12-fold
(sTCC) (Fig. 2a, Additional file 1: Table S1). The highest
Fig. 2 Synovial fluid concentrations of C4d, C3bBbP and soluble terminal complement complex (sTCC). a Box plots with subjects ordered by the
diagnostic groups: reference, osteoarthritis (OA), rheumatoid arthritis (RA), pyrophosphate arthritis (PPA), and knee injuries split into recent injury
and old injury. b Knee injury samples ordered by days after injury in subgroups of 24–46 subjects (Table 1), showing recent injury and old injury
groups. Boxes show the quartiles (median, 25th and 75th percentiles) with error bars and whiskers for the 10th and 90th percentiles. The quartiles
of the reference group are extended as thin horizontal lines in both panels for comparison. Statistically significant group differences, determined
by Mann-Whitney U test, versus the reference group are indicated by asterisks (*) and are presented in Additional file 1: Table S1. CAU Comple-
ment activation units
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synovial fluid concentrations of C4d, C3bBbP and sTCC
were found in the RA group (Fig. 2a, Additional file 1:
Table S1).
The synovial fluid concentrations of C4d, C3bBbP and
sTCC did not differ between men and women in the dif-
ferent subject groups (Additional file 3: Table S3). The
subjects in the OA, RA and PPA groups were older than
the subjects in the reference group (Table 1). Also, there
was a positive correlation in the OA and PPA groups be-
tween age and concentrations of sTCC, and in the refer-
ence group for C4d; no other correlation between age
and concentration of complement products was found
in the subject groups (Additional file 3: Table S3). On
one hand, this suggests that, compared with the refer-
ence group, the increased levels of C3bBbP in the OA,
RA and PPA groups, as well as the increased levels of
sTCC in the RA group, were due to disease mechanisms
and not to differences in age. On the other hand, the in-
creased levels of C4d in the OA, RA and PPA groups, as
well as the increased levels of sTCC in the OA and PPA
groups, could also be due partially to differences in age
between the disease and reference groups.
Concentrations of C4d, C3bBbP and sTCC in synovial fluid
were higher in the knee injury group than in the
reference group
The concentrations of C4d, C3bBbP and sTCC were
higher in the knee injury group than in the reference
group, with median increases of 7-, 5- and 4-fold, re-
spectively (Fig. 2a, Additional file 1: Table S1). The syn-
ovial fluid concentrations of C4d, C3bBbP and sTCC did
not differ between men and women in the knee injury
group (Additional file 3: Table S3). There was no differ-
ence in mean age between the reference group and the
knee injury group (0–37 years after injury), or between
the reference group and the recent injury (0–83 days
after injury) and old injury (1–37 years after injury) sub-
groups (Table 1). This suggests that the increased levels
of activated complement products in the synovial fluid
of injured knees compared with reference knees were
due to the knee trauma.
The elevated concentrations of C4d, C3bBbP and
sTCC were seen immediately after injury (day 0, the day
of injury) as 12-, 10- and 12-fold increases of median
levels compared with the reference group, with a lower
still significantly elevated level in knees aspirated over
the first 12 weeks after injury (Fig. 2b, Additional file 1:
Table S1). As seen by using correlation analysis, the syn-
ovial fluid concentrations of C4d, C3bBbP and sTCC in
the recent injury group (0–83 days after injury) de-
creased with time after injury (Fig. 2b, Additional file 3:
Table S3), while no lower levels were observed over later
times in the old injury group (1–37 years after injury)
(Additional file 3: Table S3). Many years after injury, the
synovial fluid concentration of C4d was still elevated 2-
fold compared with levels in the reference group (Fig. 2b,
Additional file 1: Table S1), although this increase could
be due in part to the fact that some patients in the old
injury group had post-traumatic OA (Table 1).
Correlation between activated complement products
In all the subject groups, the synovial fluid concentra-
tions of C4d and sTCC showed a moderate to strong
positive correlation (Table 2). In the reference, RA and
knee injury groups, there was a moderate to strong
positive correlation between C4d and C3bBbP, and in
the RA and knee injury groups, there was also a moder-
ate positive correlation between C3bBbP and sTCC
(Table 2).
Correlation between activated complement products and
other biomarkers in the recent injury group
For the recent injury group (0–83 days after injury), we
performed a correlation analysis between synovial fluid
concentrations of the activated complement factors and
the levels of proinflammatory cytokines and biomarkers
of cartilage (sGAG, ARGS-aggrecan, COMP and C2C)
and bone (osteocalcin, SPARC and osteonectin). A weak
to moderate positive correlation was found for the C4d,
C3bBbP and sTCC concentrations and the levels of cyto-
kines, where C4d and TNF showed the strongest correl-
ation (rs = 0.547). No correlation was found between the
concentrations of activated complement products and
the levels of aggrecan markers sGAG and ARGS-
aggrecan or between activated complement products
and COMP (Table 3). A weak negative correlation was
found between the concentrations of type II collagen
epitope C2C and the level of C4d. Also, C4d, C3bBbP
and sTCC concentrations showed weak to moderate
positive correlations with the levels of SPARC, and con-
centrations of C4d and C3bBbP had a weak positive cor-
relation with the levels of osteocalcin (Table 3).
Association between activated complement products and
MRI findings in the recent injury group
For a subset of the recent injury group, we compared
MRI features with synovial fluid concentrations of the
complement factors. Knees with any OC fracture (with
or without disrupted cortical bone) had higher concen-
trations of C4d and sTCC than knees without an OC
fracture (Table 4). Knees with an OC fracture with dis-
rupted cortical bone had higher concentrations of C4d
and sTCC than knees without an OC fracture, and they
also higher concentrations of C4d than knees with an
OC fracture without disrupted cortical bone (Table 4).
There were no significant differences between knees
with an OC fracture without disrupted cortical bone and
knees without OC fracture (data not shown). There was
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no difference in the synovial fluid concentrations of the
complement factors between knees that acquired an
ACL injury and knees without an ACL injury, although
knees with a meniscal tear had lower concentrations of
sTCC than knees without a meniscal tear (Table 4).
Discussion
Using synovial fluid from subjects in different diagnostic
groups, we show that C4d, C3bBbP and sTCC concen-
trations were elevated not only in our positive controls
RA and PPA but also in OA knees and in knee injury
compared with levels in the healthy reference group
knees. In injured knees, this increase was immediate,
seen in knees aspirated on the day of injury, compared
with lower levels in knees aspirated up to weeks after in-
jury. Compared with levels of reference knees, knees
aspirated several years after injury only showed elevated
levels of C4d.
Complement C4d fragment (a proteolytic fragment
of C4 with unknown biological function) is an early-
stage marker for the classical and lectin pathways,
C3bBbP (a C3 convertase) is an early stage marker for
the alternative pathway, and sTCC (also known as
membrane attack complex [MAC]) is a late-stage
marker for all three pathways [1]. In autoimmune dis-
eases such as RA, all three pathways are activated [3].
Analysis of synovial fluid by mass spectrometry and
ELISA has shown that levels of complement compo-
nents are elevated in patients with OA compared with
levels found in healthy individuals [25–27]. Further,
patients with OA had increased synovial fluid concen-
trations of C3a, an anaphylatoxin (i.e., stimulator of
inflammation) that can be generated from all three
pathways, and of sTCC compared with levels in
healthy control subjects [27]. Our results confirm that
patients with OA have increased concentrations of
sTCC, and they extend previous findings by showing
that the alternative pathway, together with the clas-
sical and/or lectin complement pathways, was acti-
vated in the synovial fluid of patients with OA and
after knee injury.
Complement factors present in the synovial fluid after
knee trauma may originate from intra-articular bleeding
(i.e., haemarthrosis from the ligaments and/or from the
synovium) or may be produced by synovial cells (leuco-
cytes and synoviocytes) and/or chondrocytes [27–31].
Joint bleeding is very common after acute knee injury,
and 96 of the 98 recent injury samples with available
MRI data had haemarthrosis in our study. At the mo-
ment of knee trauma, impact forces can also result in
BMLs and OC fractures visualized by MRI. On the basis
of previous evidence [24], we anticipated that the pres-
ence of OC fractures could be used as a proxy for a
strong impact trauma and that disruption of the cortical
bone may be an indicator of more severe joint trauma.
Complement is involved in fracture healing, where it
Table 2 Correlation between C4d, C3bBbP and sTCC in reference and patient groups
Reference (n = 23) Osteoarthritis (n = 24) Rheumatoid arthritis (n = 32)
C4d C3bBbP C4d C3bBbP C4d C3bBbP
C3bBbP 0.428 (0.041) – 0.080 (0.710) – 0.536 (0.002) –
sTCC 0.625 (0.001) 0.409 (0.053) 0.754 (<0.001) –0.298 (0.157) 0.752 (<0.001) 0.509 (0.003)
Pyrophosphate arthritis (n = 25) Knee injury (n = 294)
C4d C3bBbP C4d C3bBbP
C3bBbP –0.085 (0.685) – 0.674 (<0.001) –
sTCC 0.496 (0.012) 0.345 (0.091) 0.643 (<0.001) 0.494 (<0.001)
sTCC Soluble terminal complement complex
Correlation using Spearman’s rho (rs) between synovial fluid biomarkers of complement system analysed in different subject groups. Significant correlations
(p < 0.05) are indicated by boldface type. The table shows rs with p values in brackets
Table 3 Correlation between C4d, C3bBbP, sTCC and other
biomarkers in the recent injury group
Biomarkers n C4d C3bBbP sTCC
IL-1β 112 0.397 (<0.001) 0.232 (0.014) 0.297 (0.001)
IL-6 112 0.364 (<0.001) 0.235 (0.013) 0.268 (0.004)
IL-8 112 0.355 (<0.001) 0.183 (0.054) 0.372 (<0.001)
TNF-α 112 0.547 (<0.001) 0.317 (0.001) 0.391 (<0.001)
sGAG 181 0.108 (0.148) 0.092 (0.218) 0.132 (0.077)
ARGS 111 −0.023 (0.811) −0.113 (0.238) 0.176 (0.065)
COMP 112 −0.019 (0.845) −0.149 (0.116) −0.057(0.549)
C2C 164 −0.181 (0.020) −0.101 (0.197) −0.085 (0.279)
Osteocalcin 112 0.265 (0.005) 0.192 (0.043) 0.016 (0.871)
SPARC 112 0.476 (<0.001) 0.221 (0.019) 0.401 (<0.001)
Osteopontin 112 0.167 (0.079) 0.098 (0.302) 0.165 (0.083)
Abbreviations: IL Interleukin, TNF-α Tumour necrosis factor α, sGAG Sulfated
glycosaminoglycan, ARGS ARGS-aggrecan, COMP Cartilage oligomeric matrix
protein, C2C Type II collagen epitope, SPARC Secreted protein acidic and rich
in cysteine, sTCC Soluble terminal complement complex
Correlation using Spearman rho (rs), between synovial fluid biomarkers was
analysed in samples from the recent injury group (0–83 days after injury).
Significant correlations (p < 0.05) are shown in boldface type. The table shows
rs with p values in brackets. References to biomarkers: cytokines, ARGS, sGAG,
osteocalcin, SPARC, osteopontin [14], COMP [19], C2C [23]
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affects osteoblasts and osteoclasts. These bone cells also
produce C3 and C5, and type I collagen is capable of ac-
tivating platelets, forming sTCC and upregulating recep-
tors for C3a and C5a [32, 33]. At the fracture edge of
matrix cracks, the chondrocyte death rate is very high,
and damage-associated molecular patterns released from
dying cells (i.e., cellular debris such as mitochondria, his-
tones, DNA) contributes to an activation of the innate
system [10, 32, 34] and directly triggers C1q [35]. Fur-
ther, factor VII-acting serine protease, an activator of the
coagulation system that is activated by DNA and his-
tones, together with plasmin and clotting factors (e.g.,
thrombin and factor Xa) can generate C3a/C3b and
C5a/C5b [32, 36]. Together, this might explain why pa-
tients with knee injury with OC fractures who have
major cell osteocyte and chondrocyte death and intra-
articular bleeding also have increased complement factor
activation of C4d and sTCC compared with patients
without such fractures, as shown in our present study.
Previously, we showed that patients with recent knee
injury have signs of cartilage degradation, as reflected by
an increased release into synovial fluid over several
weeks of proteolytic products of aggrecan, type II colla-
gen and COMP [14–17, 19, 23, 37, 38]. Many of the
ECM proteins and their fragments, such as aggrecan,
chondroadherin, fibromodulin and osteoadherin, activate
the classical complement pathway [6, 7, 27, 39], while
others, such as COMP and type II collagen, activate the
alternative pathway [5, 40]. However, several ECM pro-
teins also inhibit complement: Proline/arginine-rich end
leucine-rich repeat protein (PRELP) and the NC4 do-
main of type IX collagen directly inhibit formation of
MAC [41, 42]; biglycan, decorin and COMP inhibit the
classical pathway via binding of C1q [5, 43]; and PRELP
inhibits the alternative pathway [41]. The ECM proteins
and their fragments thus seem to have dual effects on
complement, either activating or inhibiting it. This dual-
ity could in part explain why in the synovial fluid from
the recent injury group no correlations were found be-
tween the cartilage protein fragments and the compo-
nents of the different complement pathways.
Compared with individuals with healthy knees, TNF-
α concentrations in synovial fluid are increased in pa-
tients with OA and also in patients with recent (weeks)
as well as old (years) knee injuries [14, 38, 44–46].
Interestingly, in this study, the strongest correlation for
the recent injury group samples (0–83 days after injury)
was between synovial fluid concentrations of C4d and
TNF-α (rs = 0.547), and the levels of C4d were also
found to be elevated many years after injury. This re-
sembles what was found for patients with ACL injury,
who had elevated synovial fluid levels of TNF-α 5 years
after injury [38].
In injured knee joints, proinflammatory cytokines
are produced by chondrocytes and synoviocytes and
by infiltrated leucocytes, resulting in the production
and activation of matrix metalloproteases (MMPs) and
aggrecanases [11, 47, 48]. As a parallel route, comple-
ment components such as sublytic concentrations of
MAC stimulate chondrocytes to produce MMPs and
Table 4 C4d, C3bBbP, sTCC concentrations in the recent injury group in relation to structural features
Any OC fracture (n = 67) vs. No OC fracture (n = 31) vs. OC fracture with disrupted
cortical bone (n = 38)
vs. OC fracture without disrupted
cortical bone (n = 29)
Mean (95 % CI) p value Mean (95 % CI) p value Mean (95 % CI) p value Mean (95 % CI)
C4d 38.90 (32.01–47.29) 0.014 23.92 (15.17–37.70) 0.004 45.42 (33.95–60.79) 0.025 31.76 (25.00–40.35)
C3bBbP 235.61 (203.19–273.15) 0.478 213.60 (162.33–281.06) 0.612 237.30 (195.79–287.61) 0.637 233.35 (182.64–298.19)
sTCC 12.81 (11.35–14.47) 0.004 9.27 (7.20–11.94) <0.001 14.26 (12.20–16.68) 0.056 11.13 (9.20–13.46)
ACL injury
(n = 60)
vs. No ACL injury (n = 38)
Mean (95 % CI) p value Mean (95 % CI)
C4d 34.34 (28.39–41.52) 0.418 31.86 (20.87–48.66)
C3bBbP 231.42 (198.93–269.28) 0.417 223.67 (174.62–286.48)
sTCC 11.53 (10.26–12.97) 0.885 11.61 (9.08–14.85)
Meniscal tear (n = 43) vs. No meniscal tear (n = 55)
Mean (95 % CI) p value Mean (95 % CI)
C4d 29.36 (21.57–39.98) 0.565 36.86 (28.42–47.80)
C3bBbP 204.27 (172.78–241.49) 0.399 249.23 (205.21–302.69)
sTCC 9.91 (8.46–11.62) 0.013 13.05 (11.08–15.37)
Abbreviations: ACL Anterior cruciate ligament, OC Osteochondral, sTCC Soluble terminal complement complex
Magnetic resonance imaging results were available for a subfraction of the recent injury group (n = 98). Between-groups statistical testing was performed using analysis
of covariance of log10-transformed concentrations with adjustment for days between the injury and synovial fluid aspiration, age at injury, and sex. Significant
differences (p < 0.05) are shown in boldface type. Concentrations in complement activation units are presented as linear data as means with 95 % CI in brackets
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aggrecanases [27], and complement anaphylatoxins
(C3a and C5a) stimulate granulocytes, macrophages,
and B and T cells to produce proinflammatory cyto-
kines [3]. Further, it has been shown that C1s (a prote-
ase of the classical pathway) can activate proMMP-9,
and C1s can also cleave types I, II and IV collagens
[49, 50]. This indicates that there are several possible
routes for the induction of extracellular proteases in
these patients.
In patients with a recent knee injury (0–5 weeks), the
release into the synovial fluid of proinflammatory cyto-
kines IL-1β, IL-6 and TNF-α precedes the release of car-
tilage degradation products of aggrecan, COMP and
type II collagen [14, 19, 23, 38]. In the same patients in
the present study, we found no correlation between the
complement factors C4d, C3bBbP and sTCC and cartil-
age degradation products of aggrecan, type II collagen
and COMP; however, the complement factor concentra-
tions correlated positively with proinflammatory cyto-
kine levels of IL-1β, IL-6 and TNF-α. This supports the
concept that complement together with coagulation rep-
resents an alternative route to activation of cytokine
pathways, and together these routes drive the catabolic
process seen as cartilage degradation after joint injury
and most likely later in OA.
This study has certain limitations. First, the lack of di-
lution linearity for the C3bBbP and sTCC assays using
synovial fluid samples complicated the assessments, and
only relative comparison could be made by using the
same dilution (1:20) for all samples. Second, because the
subjects in the OA, RA and PPA groups were older than
the subjects in the reference group, we cannot exclude
the possibility that the increased levels of the comple-
ment factors found in these patient groups could be due
partly to differences in age. Third, the knee injury group
was cross-sectional, so the design precludes drawing
firm conclusions of trends in time because no repeated
sampling was done within individual patients. Hence,
our suggestions regarding differences in complement ac-
tivation over time need to be confirmed in longitudinal
studies. Finally, we measured only the soluble compo-
nents of C4d, C3bBbP and sTCC found in synovial fluid,
and these also ought to be analysed as cell-bound (e.g.,
chondrocytes, synoviocytes) components for the differ-
ent diagnostic groups.
Conclusions
We show that alternative and classical and/or lectin
complement pathways are activated in the synovial fluid
of subjects with knee injury and in patients with OA.
After an injury to the knee, the complement factors
C4d, C3bBbP and sTCC are instantly activated and are
associated with proinflammatory cytokines, while C4d
and sTCC are associated with OC fractures.
This and previous reports have suggested that
complement is activated in OA [27]. Knee injury is a
well-known and strong risk factor for rapid knee OA
development, but the driving mechanisms are not well
understood. The sudden activation of complement after
knee injury found in this study, especially among those
with more severe trauma, most likely represents one of
several important pathways involved in the onset of this
complex disease. Therefore, more clinical studies using
longitudinal cohorts are needed to elucidate these
pathological pathways to determine if or when to use
complement inhibitors as a treatment strategy for OA.
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